Biotech entity
Of the tracked stories, 2 of 2 also mention Biden Administration, the most common co-covered peer. Source depth averages 3.5 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 6.5 runs above the beat's 5.8 for that window.
Last mentioned: Aug 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Biden Administration, the most common co-covered peer. Source depth averages 3.5 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 6.5 runs above the beat's 5.8 for that window. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Biotech stories mentioning Dr. Mehmet Oz across the period from July 30, 2026 to August 1, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 26 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Mehmet Oz. Shared-story counts are live from our verified record — not editorial picks.
Subsidy Program Ends
The temporary premium subsidy officially concludes; beneficiaries may face higher monthly costs unless insurers absorb the cost or new policies emerge.
2027 Premiums Announced Amid Elections
Part D plan rates for 2027 are released in the fall, coinciding with November midterm elections where cost of living is a top issue.
CMS Announces Subsidy Program Will End
Administrator Dr. Mehmet Oz announces the subsidy will conclude in 2027, citing $3.6B in taxpayer costs for 2026 and a desire to stop subsidizing insurers.
Drug Price Cuts Take Effect
Lower negotiated prices for 10 popular and expensive drugs begin for Part D enrollees, as mandated by the IRA.
Biden Administration Implements Temporary Part D Subsidy
A subsidy program is launched to offset premium increases for Medicare Part D enrollees caused by the IRA’s benefit changes.
Inflation Reduction Act Signed
Legislation includes drug price negotiation and Part D benefit redesign, setting the stage for higher base premiums that later necessitate a temporary subsidy.
The elimination of a $3.6 billion Medicare Part D subsidy may raise drug costs for seniors, potentially reducing adherence and impacting pharmaceutical manufacturers' market outlook. The move adds to pricing pressures from the Inflation Reduction Act.
Source: nbcbayarea.com · nbcnewyork.com
Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.
Source: orlandosentinel.com · citizensvoice.com
Dr. Mehmet Oz is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
